Rigel Pharmaceuticals, Inc.
NASDAQ:RIGLBiotechnology
-$0.62 today
- Market cap
- $808.18M
- Beta
- 1.18
- P/E (TTM)
- 1.7
- EPS (TTM)
- $19.78
Volume 0.24M
Average 0.36M
RIGL EBITDA Margin
EBITDA as a percentage of revenue.
Rigel Pharmaceuticals, Inc.NASDAQ: RIGL
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin narrows to 23.3%
EBITDA Margin was 23.3% in Q1 FY2026, down 2.9 pp from a year earlier. On a trailing-twelve-month basis it was 43.8%, up 19.9 pp year over year. Over 3 fiscal years it widened by 89.5 pp.
Context
- EBITDA Margin widened in 3 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 4 analysts of 29.5% for the fiscal year ending Dec 2026, down from 44.7% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- 23.3%-12.6 pp QoQ
- Last fiscal yearDec 2025
- 44.7%+28.8 pp YoY
- LTMMar 2026
- 43.8%+19.9 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -2.9 pp | -54.4 pp | -51.5 pp |
| 1 year | +28.8 pp | -15.2 pp | -44.0 pp |
| 3 years | +89.5 pp | -7.6 pp | -97.1 pp |
| 5 years | -16.8 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- 44.7%
- Year-over-year change
- +28.8pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 44.7% | +28.8pp |
| FY2024 | 2024-12-31 | 15.9% | +30.4pp |
| FY2023 | 2023-12-31 | -14.5% | +30.3pp |
| FY2022 | 2022-12-31 | -44.8% | -37.2pp |
| FY2021 | 2021-12-31 | -7.6% | — |
EBITDA Margin vs competitors
How RIGL compares with its peers on the latest reported figures
- RIGL's LTM Mar 2026 EBITDA Margin of 43.8% is the 2nd highest of the 8 companies compared; the peer median is -387.1%.
- Its year-over-year change of +19.9 pp is the 3rd highest of 6, against a peer median of +6.3 pp.
- Over three fiscal years its change of +89.5 pp compares with a peer median of +147.4 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Aug 2026 | 46.0% | +315.4 pp | +147.4 pp | |
| LTM Mar 2026 | 43.8% | +19.9 pp | +89.5 pp | |
| LTM Jul 2026 | 43.0% | +6.3 pp | +23.9 pp | |
| LTM Mar 2026 | -287.9% | -44.6 pp | +113.4 pp | |
| LTM Mar 2026 | -387.1% | +1063.3 pp | +2084.9 pp | |
| LTM Jun 2024 | -979.5% | — | — | |
| LTM Mar 2026 | -7858.4% | — | — | |
| LTM Mar 2026 | -8329.5% | -111.2 pp | +2386.2 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding RIGL) | -387.1% | +6.3 pp | +147.4 pp | |
Competitors are the stored peer set for RIGL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 149.24M | 120.24M | 116.88M | 179.28M | 294.28M |
| Cost of Revenue | 1.08M | 1.75M | 7.11M | 18.65M | 19.62M |
| Gross Profit | 148.15M | 118.49M | 109.77M | 160.63M | 274.66M |
| Gross Margin | 99.3% | 98.5% | 93.9% | 89.6% | 93.3% |
| Research & Development | 65.24M | 60.27M | 24.52M | 23.38M | 33.3M |
| Selling, General & Admin | 91.89M | 112.45M | 105.74M | 113.06M | 115.9M |
| Operating Expenses | 160.65M | 174.04M | 130.26M | 136.44M | 149.2M |
| Depreciation & Amortization | 1.16M | 998K | 1.24M | 2.23M | 2.42M |
| EBITDA | (11.29M) | (53.87M) | (16.98M) | 28.51M | 131.56M |
| EBITDA Margin | -7.6% | -44.8% | -14.5% | 15.9% | 44.7% |
| Operating Income | (12.5M) | (55.55M) | (20.49M) | 24.19M | 125.47M |
| Operating Margin | -8.4% | -46.2% | -17.5% | 13.5% | 42.6% |
| Interest Income | 47K | 684K | 2.27M | 2.09M | 3.68M |
| Interest Expense | 4.86M | 3.71M | 6.87M | 7.92M | 7.32M |
| Other Income / Expenses | (4.81M) | (3.02M) | (4.6M) | (5.83M) | (3.64M) |
| Income Before Tax | (17.31M) | (58.57M) | (25.09M) | 18.37M | 121.83M |
| Pre-Tax Margin | -11.6% | -48.7% | -21.5% | 10.2% | 41.4% |
| Income Tax Expense | 605K | 0 | 0 | 881K | (245.2M) |
| Net Income | (17.91M) | (58.57M) | (25.09M) | 17.49M | 367.02M |
| Net Margin | -12.0% | -48.7% | -21.5% | 9.8% | 124.7% |
| EPS (Basic) | (1.10) | (3.40) | (1.44) | 0.99 | 20.40 |
| EPS (Diluted) | (1.10) | (3.40) | (1.44) | 0.99 | 19.48 |
| Weighted Avg Shares | 17.05M | 17.24M | 17.4M | 17.58M | 17.99M |
| Weighted Avg Shares (Diluted) | 17.05M | 17.24M | 17.4M | 17.69M | 18.84M |
Rigel Pharmaceuticals, Inc.
NASDAQ:RIGL
Intrinsic Alpha fair value
Locked
Current Price
$42.92
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.